HSIN-YUN SUNSingh N.2020-12-292020-12-2920100924-8579https://www.scopus.com/inward/record.uri?eid=2-s2.0-73549099328&doi=10.1016%2fj.ijantimicag.2009.09.020&partnerID=40&md5=2793f007a46164d1c6c721e8df8d34e8https://scholars.lib.ntu.edu.tw/handle/123456789/535297The echinocandins have emerged as important antifungal agents in the current era. Despite their potent antifungal activity, breakthrough invasive mycoses occur in echinocandin recipients, however their precise incidence and causative pathogens are not well delineated. This review shows that breakthrough mycoses occur in 2.4% of patients receiving echinocandins as prophylaxis and are predominantly due to non-albicans Candida spp. and less frequently to invasive aspergillosis. Candida isolates demonstrating reduced susceptibility occurred following prolonged exposure to the echinocandins, primarily in severely immunocompromised patients, and manifested as recurrent episodes of candidaemia or invasive candidiasis.[SDGs]SDG3anidulafungin; antineoplastic agent; caspofungin; echinocandin; micafungin; antifungal activity; antifungal resistance; antifungal susceptibility; aspergillosis; Candida; candidiasis; cryptococcosis; disease activity; disease severity; drug efficacy; drug indication; drug use; esophagitis; evidence based medicine; fungal strain; fungemia; fungus isolation; fusariosis; human; immune deficiency; incidence; minimum inhibitory concentration; mucormycosis; mycosis; myelodysplastic syndrome; nonhuman; otitis; primary prevention; priority journal; short survey; treatment duration; treatment response; Antifungal Agents; Chemoprevention; Drug Resistance, Fungal; Echinocandins; Fungi; Humans; Incidence; Mycosesshort survey10.1016/j.ijantimicag.2009.09.02020036518